PDCD1 and neoplasm: Finally, anti-PD1 induced the rejection of 12-day-established 1956 tumours in Δ1+2+3 mice but not in WT mice (Fig. 5h), suggesting that the enhanced efficacy of anti-PD1 in the absence of cDC2s and/or monocytes was manifested, at least in part, by the failure to generate cytotoxic Tr1 cells.